还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

3 t  ^( t& n& M- s3 d5 O                               
登录/注册后可看大图

9 u) I+ R8 H( L% _1 Z; N请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
  T% T0 G, Q2 \/ {
9 K2 l9 C- e4 L( @$ ^2 ^- P4 c8 K
Sub-category:
5 ]5 ^3 q, \7 T/ M8 |5 zMolecular Targets

9 H# \/ @: o% H
Category:
Tumor Biology


8 q9 i+ D! Y8 Z& F: kMeeting:
2011 ASCO Annual Meeting
1 j; l  {; m, Q7 v
2 O8 |" |8 B4 z/ [% H
0 a/ L6 n; m. ^0 N/ L+ S0 u; fSession Type and Session Title:
Poster Discussion Session, Tumor Biology

* a9 A; P8 ?. v4 C3 Y; \4 L" A
8 D5 G* X  T* t1 MAbstract No:
* v" V+ d+ s4 y( n  ?- E- t10517


( E( T5 a6 s$ U! v5 z4 HCitation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
. _& n7 c3 f  \) e
5 X5 O1 G: j2 k4 K- O8 ^
' l9 Z) R- F2 \Author(s):
3 H* Q# O5 L; H' v* G+ x, OJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
* ]8 E; k/ g9 P% Z$ ]4 p- R% }9 b& @


Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
0 F! B0 P" H4 t5 I2 E
" h8 X- p2 V$ O5 iAbstract Disclosures
- I: ]8 m- e0 x3 X9 k# c
Abstract:
) ~. @0 N( L/ U2 q6 h: m
: d- H: e. f! @9 o
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

6 t/ k* n- X! n# y

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

% d+ c, a% y' b                               
登录/注册后可看大图

! v. E! F6 |" g  ^( k没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

6 b& f2 p- N5 y. q0 T* g, c/ k7 D; G化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

. l$ t1 `" E1 S. E, m" ^# e0 x* `$ W* v                               
登录/注册后可看大图

易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
9 B6 F% S' i9 ~3 MALK一个指标医院要900多 ...

& m! H0 }2 S/ s2 g7 j平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？

现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊